NasdaqGM - Delayed Quote USD

Alimera Sciences, Inc. (ALIM)

3.3400 -0.1000 (-2.91%)
At close: 4:00 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Richard S. Eiswirth Jr. CEO & Director 597.87k -- 1968
Mr. David R. Holland Co-Founder, Chief Marketing Officer and Senior VP of Corporate Communications & Managed Markets 413.5k -- 1964
Dr. Philip Ashman Ph.D. President of International Operations 389.86k -- 1965
Mr. Todd Michael Wood President of U.S. Operations -- -- 1970
Mr. Elliot Maltz CPA CFO & Treasurer -- -- 1985
Mr. Jason Werner Chief Operating Officer -- -- --
Christopher S. Visick VP, General Counsel & Secretary -- -- --
Dr. David Dyer M.D. Chief Retina Specialist -- -- --

Alimera Sciences, Inc.

6310 Town Square
Suite 400
Alpharetta, GA 30005
United States
678 990 5740 https://alimerasciences.com
Sector: 
Healthcare
Full Time Employees: 
154

Description

Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

Corporate Governance

Alimera Sciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 13, 2024 - May 17, 2024
Alimera Sciences, Inc. Earnings Call

Related Tickers

EOLS Evolus, Inc.
11.53
-0.26%
 
INDV Indivior PLC
18.52
-1.28%
 
ALKS Alkermes plc
23.85
+0.38%
 
HROW Harrow, Inc.
10.45
-3.69%
 
ANIP ANI Pharmaceuticals, Inc.
65.48
+1.39%
 
RICH.BA Laboratorios Richmond S.A.C.I.F.
874.50
+0.17%
 
DCPH Deciphera Pharmaceuticals, Inc.
14.67
+3.09%
 
HCANF Halo Collective Inc.
0.0000
0.00%
 
VIT.AX Vitura Health Limited
0.1600
-5.88%
 
IRWD Ironwood Pharmaceuticals, Inc.
7.92
+4.21%